Blueprint Medicines Corporation 8-K Report: Key Insights & Stock News
Based on the provided section of the financial report, here are the key pieces of information:
- Entity Information:
- Company Name: Blueprint Medicines Corporation
- CIK: 0001597264
- Industry: Biotechnology (inferred from the company name)
- Address: 45 Sidney Street, Cambridge, MA 02139
- Phone Number: 617-374-7580
- NASDAQ Ticker Symbol: BPMC
- Filing Details:
- Filing Type: 8-K (which indicates a current report to disclose significant events)
- Filing Date: February 13, 2025
- Stock Information:
- Common Stock Par Value: $0.001 per share
- Period of Reporting:
- Start Date: February 13, 2025
- End Date: February 13, 2025
- Additional Metadata:
- The document includes references to XML schema and is structured in XBRL (eXtensible Business Reporting Language), which is commonly used for financial reporting.
Insights:
- The filing is an 8-K, suggesting that Blueprint Medicines Corporation is reporting a significant event or change that could be relevant to investors.
- The filing date coincides exactly with the reporting period, indicating this may be a timely or immediate disclosure.
- The company operates in the biotechnology sector, which is often characterized by high volatility and potential for significant growth or decline based on clinical trial results or regulatory approvals.
This information is crucial for investors and analysts monitoring the company’s activities and its implications for stock performance.